Menu
Sign In Search Podcasts Libraries Charts People & Topics Add Podcast API Blog Pricing

AbbVie in Podcasts

company

AbbVie, a pharmaceutical company that acquired Gilgamesh, a company developing psychedelic compounds.

Mentions Over Time

6 mentions

Mentions in Podcasts

The Claire Byrne Show
A landmark breakthrough in ovarian cancer treatment 

I suppose it is worthwhile saying that AbbVie, who is the company who owns this drug, they opened a compassionate access programme for our patients.

The Claire Byrne Show
The exchequer reliance on corporate tax

AbbVie, $431 million.

WSJ What’s News
What’s News in Earnings: How Big Pharma Is Expanding the GLP-1 Market

AbbVie actually raised its sales guidance for its two main autoimmune drugs, Skyrizzy and Renvoke.

WSJ What’s News
What’s News in Earnings: How Big Pharma Is Expanding the GLP-1 Market

Elsewhere in pharma, companies are mostly delivering positive results, with Merck, Bristol-Myers Squibb and AbbVie all posting earnings beats.

Wall Street Breakfast
Earnings season begins as Trump threatens Hormuz blockade

And for income investors, Abbott Labs and AbbVie go ex-dividend on Wednesday with payouts scheduled for May 15th.

Motley Fool Hidden Gems Investing
The Psychedelic Revolution

And there was a high-profile acquisition in, I think it was August of last year, when Gilgamesh was bought by AbbVie on the basis of a psychedelic compound that's called Brettosilicin.